HIV biotech Calimmune bags $15M to move one-time gene therapy into new trials

Desert Angels portfolio company, Calimmune, just landed a $15 million B round, positioning the biotech to launch new trials with a gene therapy designed to durably stymie the lethal HIV with one treatment.

Click here for full article